HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Diagnostic and progression biomarkers in cerebrospinal fluid of Alzheimer's disease patients.

Abstract
In this commentary, we address a paper published by Johnson et al. by assessing the robustness of their method to discover diagnostic biomarkers in Alzheimer's disease (AD). In addition, we examine how these newly discovered and previously discovered biomarkers, can play a role in assisting patients with AD and those at risk for developing AD, with an emphasis on the translational hurdles that accompany such discoveries.
AuthorsMiyo K Chatanaka, Ioannis Prassas, Eleftherios P Diamandis
JournalBMC medicine (BMC Med) Vol. 22 Issue 1 Pg. 60 (02 08 2024) ISSN: 1741-7015 [Electronic] England
PMID38331825 (Publication Type: Journal Article)
Copyright© 2024. The Author(s).
Chemical References
  • Amyloid beta-Peptides
  • Biomarkers
Topics
  • Humans
  • Alzheimer Disease (diagnosis)
  • Amyloid beta-Peptides (cerebrospinal fluid)
  • Biomarkers
  • Disease Progression

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: